<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02035696</url>
  </required_header>
  <id_info>
    <org_study_id>V58P16</org_study_id>
    <secondary_id>2013-002081-39</secondary_id>
    <nct_id>NCT02035696</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of a Four Influenza Vaccines in Children Ages 6 Months Old to Less Than 48 Months Old</brief_title>
  <official_title>A Phase I/II, Randomized, Observer-Blind, Multicenter Study to Evaluate Immunogenicity and Safety of Four Influenza Vaccines in Healthy Pediatric Subjects 6 to &lt; 48 Months of Age.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seqirus</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seqirus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and immunogenicity of four influenza vaccines in children 6 months to
      &lt; 48 months of age
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ratios of Geometric Mean Titer (GMT) in Subjects (6 to &lt;48 Months Old) After Receiving Two Doses of Either TIVc or TIVe Vaccine</measure>
    <time_frame>Day 50/Day 1</time_frame>
    <description>Immunogenicity was assessed in terms of ratios of GMTs in subjects (6 to &lt;48 months old), measured by hemagglutination inhibition (HI) assay, day 1 to day 50 after vaccination with two doses of either TIVc or TIVe vaccine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentages of Subjects (6 to &lt;48 Months Old) Achieving Seroconversion or Significant Increase After Receiving Two Doses of Either TIVc or TIVe Vaccine</measure>
    <time_frame>Day 50 post vaccination</time_frame>
    <description>Immunogenicity was assessed in terms number (%) of subjects (6 to &lt;48 months old) achieving seroconversion as measured by HI antibody titer, day 50 after vaccination with two doses of either TIVc or TIVe vaccine Seroconversion was defined as subjects with either a pre-vaccination (baseline) HI titer &lt; 1:10 and post-vaccination HI titer ≥ 1:40 or with a pre-vaccination HI titer ≥ 1:10 and a ≥ 4-fold increase in post-vaccination HI antibody titer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Desirability Index Score of Subjects (6 to &lt;48 Months Old) Reporting Severe Solicited Local and Systemic Reactions After Vaccination With Either TIVc or TIVe Vaccine</measure>
    <time_frame>Day 1 to Day 3</time_frame>
    <description>Differences in percentages of subjects (6 to &lt;48 months old) with severe local solicited AEs and severe solicited systemic AEs, 3 days after vaccination with either TIVc or TIVe vaccine was assessed in terms of an individual desirability index score (High dose, Full dose, Half dose TIVc vs. TIVe vaccine). An individual desirability index score was assigned to each (non-transformed) safety value based on predefined functions. Each desirability index score is assigned a value between 0 and 1, wherein 0 is an undesirable response and 1 is a highly desirable response.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects (6 to &lt;48 Months Old) Achieving Seroconversion or Significant Increase After Receiving Two Doses of Either TIVc or TIVe Vaccine</measure>
    <time_frame>Day 50 post vaccination</time_frame>
    <description>Immunogenicity was assessed in terms of number (%) of subjects (6 to &lt;48 months old) achieving seroconversion as measured by HI assay, day 50 after vaccination with two doses of either TIVc or TIVe vaccine
Seroconversion was defined as subjects with either a pre-vaccination (baseline) HI titer &lt; 1:10 and post-vaccination HI titer ≥ 1:40 or with a pre-vaccination HI titer ≥ 1:10 and a ≥ 4-fold increase in post-vaccination HI antibody titer
The Center for Biologics Evaluation, Research, and Review (CBER) criterion for pediatric population is that the lower bound of the two-sided 95% confidence interval (CI) for the percentage of subjects achieving seroconversion for HI antibody should meet or exceed 40%
The Committee for Medicinal Products for Human Use (CHMP) criterion for pediatric population is that the percentage of subjects achieving seroconversion or significant increase in HI antibody titers &gt;40%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects (6 to &lt;48 Months Old) Achieving HI Titer ≥1:40 After Receiving Two Doses of Either TIVc or TIVe Vaccine</measure>
    <time_frame>Day 1, Day 50 post vaccination</time_frame>
    <description>Immunogenicity was assessed in terms of number (%) of subjects (6 to &lt;48 months old) achieving HI titer ≥1:40 as measured by HI assay, day 50 after vaccination with two doses of either TIVc or TIVe vaccine
The CBER criterion for pediatric population is that the lower bound of the two-sided 95% CI for the percentage of subjects achieving an HI antibody titer ≥1:40 should meet or exceed 70%
The CHMP criterion for pediatric population is that the percentage of subjects achieving HI antibody titers ≥1:40 should be &gt;70%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Ratios (GMR) in Subjects (6 to &lt;48 Months Old) After Receiving Two Doses of Either TIVc or TIVe Vaccine</measure>
    <time_frame>Day 50 post vaccination over day 1</time_frame>
    <description>Immunogenicity was assessed in terms of GMR in subjects (6 to &lt;48 months old) as measured by HI assay, day 50 after vaccination with two doses of either TIVc or TIVe vaccine
The CHMP criterion is mean geometric ratio (GMR) &gt;2.5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Ratios (GMR) in Subjects (6 to &lt;48 Months Old) After Receiving Two Doses of Either TIVc or TIVe Vaccine</measure>
    <time_frame>Day 50 post vaccination over day 1</time_frame>
    <description>Immunogenicity was assessed in terms of GMR in subjects (6 to &lt;48 months old) as measured by MN assay, day 50 after vaccination with two doses of either TIVc or TIVe vaccine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects (6 to &lt;48 Months Old) With High Post Vaccination HI Titers (i.e. HI Titers ≥1:110, ≥1:150, ≥1:330 and ≥1:629) After Receiving Two Doses of Either TIVc or TIVe Vaccine</measure>
    <time_frame>Day 1 and Day 50 post vaccination</time_frame>
    <description>Immunogenicity was assessed in terms of number (%) of subjects (6 to &lt;48 months old) achieving post vaccination HI titers (i.e. HI titers ≥1:110, ≥1:150, ≥1:330 and ≥1:629) as measured by HI assay, day 50 after vaccination with two doses of either TIVc or TIVe vaccine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects (6 to &lt;48 Months Old) Achieving MN Titer ≥1:20 After Receiving Two Doses of Either TIVc or TIVe Vaccine</measure>
    <time_frame>Day 1 and Day 50 post vaccination</time_frame>
    <description>Immunogenicity was assessed in terms of number (%) of subjects (6 to &lt;48 months old) achieving MN titer ≥1:20 as measured by MN assay, day 50 after vaccination with two doses of either TIVc or TIVe vaccine
Post-vaccination MN titer ≥1:20 was defined as for subjects with baseline (day 1) MN titer &lt;1:10, or a minimum 2-fold increase in titer on day 50 for subjects with baseline titer ≥1:10 and corresponding 95% CI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects (6 to &lt;48 Months Old) Achieving MN Titer ≥1:40 After Receiving Two Doses of Either TIVc or TIVe Vaccine</measure>
    <time_frame>Day 1 and Day 50 post vaccination</time_frame>
    <description>Immunogenicity was assessed in terms of number (%) of subjects (6 to &lt;48 months old) achieving MN titer ≥1:40 as measured by MN assay, day 50 after vaccination with two doses of either TIVc or TIVe vaccine
Post-vaccination MN titer ≥1:40 was defined as for subjects with baseline (day 1) MN titer &lt;1:10, or a minimum 4-fold increase in titer on day 50 for subjects with baseline titer ≥1:10 and corresponding 95% CI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects (6 to &lt;48 Months Old) Reporting Solicited Local (Grading Type I) and Systemic Adverse Events (AEs) After Two Doses of Either TIVc or TIVe Vaccine</measure>
    <time_frame>Day 1 to Day 7</time_frame>
    <description>Safety was assessed in terms of number of subjects (6 to &lt;48 months old) reporting solicited local and systemic reactions, day 1 to day 7 after vaccination with two doses of either TIVc or TIVe vaccine (By Any Vaccination)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects (6 to &lt;48 Months Old) Reporting Unsolicited Adverse Events (AEs) After Two Doses of Either TIVc or TIVe Vaccine</measure>
    <time_frame>Unsolicited AEs after Each/any Vaccination from Day 1 to Day 29 and Day 29 to Day 50 , Day 1 to Day 209</time_frame>
    <description>Safety was assessed in terms of number of subjects (6 to &lt;48 months old) reporting unsolicited reactions after Each /any Vaccination from Day 1 [Post Vaccination] to Day 29 [Pre Clinic Visit] and Day 29 [Post Vaccination] to Day 50 [Pre Clinic Visit] , Serious Adverse Events (SAEs), AEs leading to New Onset of Chronic Diseases (NOCD), AEs leading to withdrawal from the study and concomitant medications (day 1 to day 209) after vaccination with two doses of either TIVc or TIVe vaccine (By Any Vaccination)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">671</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>TIVc-High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects (6 to &lt;48 months old) received two doses of 0.75 mL of TIVc vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TIVc-Full Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects(6 to &lt;48 months old) received two doses of 0.50 mL of TIVc vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TIVc- Half Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects (6 to &lt;48 months old)received two doses of 0.25 mL of TIVc vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TIVe</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects (6 to &lt;48 months old) received two doses of TIVe vaccine(IM/0.25mL -for ages 6 to &lt;36 months and IM/ 0.5 mL -for ages 36 to &lt;48 months)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Trivalent influenza vaccine (TIVc)</intervention_name>
    <arm_group_label>TIVc-High Dose</arm_group_label>
    <arm_group_label>TIVc-Full Dose</arm_group_label>
    <arm_group_label>TIVc- Half Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Trivalent influenza vaccine-licensed</intervention_name>
    <description>Licensed influenza vaccine</description>
    <arm_group_label>TIVe</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subject, male or female, 6 through &lt; 48 months of age at the time of
             enrollment, who has never previously received an influenza vaccine

          -  Individual who has a parent or guardian that can give written informed consent after
             understanding the nature of the study and are available for follow-up

        Exclusion Criteria:

          -  Individuals recently vaccinated against influenza

          -  Subjects with contraindications to receive influenza vaccine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>48 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Site 116</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 119</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 109</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 112</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 113</name>
      <address>
        <city>Ontario</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 117</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 114</name>
      <address>
        <city>West Covina</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 107</name>
      <address>
        <city>Thornton</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 108</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 111</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 121</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 101</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 104</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 105</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 106</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 103</name>
      <address>
        <city>Youngstown</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 102</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 115</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 118</name>
      <address>
        <city>Saint George</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 110</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 120</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 502</name>
      <address>
        <city>Kuopio</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 506</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 301</name>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 302</name>
      <address>
        <city>Muntinlupa</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 201</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 202</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Philippines</country>
    <country>Thailand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2014</study_first_submitted>
  <study_first_submitted_qc>January 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2014</study_first_posted>
  <results_first_submitted>August 19, 2015</results_first_submitted>
  <results_first_submitted_qc>May 22, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 27, 2017</results_first_posted>
  <disposition_first_submitted>February 6, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>March 27, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 16, 2015</disposition_first_posted>
  <last_update_submitted>September 12, 2017</last_update_submitted>
  <last_update_submitted_qc>September 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>influenza</keyword>
  <keyword>children</keyword>
  <keyword>safety</keyword>
  <keyword>tolerability</keyword>
  <keyword>immunogenicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>6 centers in the United States, 1 center in Finland, 2 centers in Thailand, 2 centers in Philippines</recruitment_details>
      <pre_assignment_details>All enrolled Subjects were included in the trial</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>TIVc-High Dose</title>
          <description>Subjects (6 to &lt;48 months old) received two doses of 0.75 mL of TIVc vaccine</description>
        </group>
        <group group_id="P2">
          <title>TIVc-Full Dose</title>
          <description>Subjects(6 to &lt;48 months old) received two doses of 0.50 mL of TIVc vaccine</description>
        </group>
        <group group_id="P3">
          <title>TIVc- Half Dose</title>
          <description>Subjects (6 to &lt;48 months old)received two doses of 0.25 mL of TIVc vaccine</description>
        </group>
        <group group_id="P4">
          <title>TIVe</title>
          <description>Subjects (6 to &lt;48 months old) received two doses of TIVe vaccine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="174"/>
                <participants group_id="P2" count="166"/>
                <participants group_id="P3" count="167"/>
                <participants group_id="P4" count="164"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="171"/>
                <participants group_id="P2" count="163"/>
                <participants group_id="P3" count="164"/>
                <participants group_id="P4" count="161"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>TIVc-High Dose</title>
          <description>Subjects (6 to &lt;48 months old) received two doses of 0.75 mL of TIVc vaccine</description>
        </group>
        <group group_id="B2">
          <title>TIVc-Full Dose</title>
          <description>Subjects(6 to &lt;48 months old) received two doses of 0.50 mL of TIVc vaccine</description>
        </group>
        <group group_id="B3">
          <title>TIVc- Half Dose</title>
          <description>Subjects (6 to &lt;48 months old)received two doses of 0.25 mL of TIVc vaccine</description>
        </group>
        <group group_id="B4">
          <title>TIVe</title>
          <description>Subjects (6 to &lt;48 months old) received two doses of TIVe vaccine</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="174"/>
            <count group_id="B2" value="166"/>
            <count group_id="B3" value="167"/>
            <count group_id="B4" value="164"/>
            <count group_id="B5" value="671"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.3" spread="11.5"/>
                    <measurement group_id="B2" value="25.0" spread="11.5"/>
                    <measurement group_id="B3" value="25.6" spread="11.5"/>
                    <measurement group_id="B4" value="25.3" spread="11.9"/>
                    <measurement group_id="B5" value="25.3" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>FEMALE</title>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="77"/>
                    <measurement group_id="B4" value="87"/>
                    <measurement group_id="B5" value="330"/>
                  </measurement_list>
                </category>
                <category>
                  <title>MALE</title>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="90"/>
                    <measurement group_id="B4" value="77"/>
                    <measurement group_id="B5" value="341"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Ratios of Geometric Mean Titer (GMT) in Subjects (6 to &lt;48 Months Old) After Receiving Two Doses of Either TIVc or TIVe Vaccine</title>
        <description>Immunogenicity was assessed in terms of ratios of GMTs in subjects (6 to &lt;48 months old), measured by hemagglutination inhibition (HI) assay, day 1 to day 50 after vaccination with two doses of either TIVc or TIVe vaccine</description>
        <time_frame>Day 50/Day 1</time_frame>
        <population>Analysis was done on Per Protocol (PP) population i.e. all subjects in the FAS Efficacy/Immunogenicity Set who are not excluded due to reasons defined prior to unblinding or analysis</population>
        <group_list>
          <group group_id="O1">
            <title>TIVc-High Dose</title>
            <description>Subjects (6 to &lt;48 months old) received two doses of 0.75 mL of TIVc vaccine</description>
          </group>
          <group group_id="O2">
            <title>TIVc-Full Dose</title>
            <description>Subjects(6 to &lt;48 months old) received two doses of 0.50 mL of TIVc vaccine</description>
          </group>
          <group group_id="O3">
            <title>TIVc- Half Dose</title>
            <description>Subjects (6 to &lt;48 months old)received two doses of 0.25 mL of TIVc vaccine</description>
          </group>
          <group group_id="O4">
            <title>TIVe</title>
            <description>Subjects (6 to &lt;48 months old) received two doses of TIVe vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Ratios of Geometric Mean Titer (GMT) in Subjects (6 to &lt;48 Months Old) After Receiving Two Doses of Either TIVc or TIVe Vaccine</title>
          <description>Immunogenicity was assessed in terms of ratios of GMTs in subjects (6 to &lt;48 months old), measured by hemagglutination inhibition (HI) assay, day 1 to day 50 after vaccination with two doses of either TIVc or TIVe vaccine</description>
          <population>Analysis was done on Per Protocol (PP) population i.e. all subjects in the FAS Efficacy/Immunogenicity Set who are not excluded due to reasons defined prior to unblinding or analysis</population>
          <units>Ratios</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="147"/>
                <count group_id="O3" value="141"/>
                <count group_id="O4" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" lower_limit="4.29" upper_limit="14"/>
                    <measurement group_id="O2" value="5.5" lower_limit="3.01" upper_limit="10"/>
                    <measurement group_id="O3" value="5.92" lower_limit="3.2" upper_limit="11"/>
                    <measurement group_id="O4" value="3.69" lower_limit="2.03" upper_limit="6.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="6.34" upper_limit="17"/>
                    <measurement group_id="O2" value="11" lower_limit="6.5" upper_limit="18"/>
                    <measurement group_id="O3" value="6.47" lower_limit="3.84" upper_limit="11"/>
                    <measurement group_id="O4" value="12" lower_limit="7.17" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.18" lower_limit="3.737" upper_limit="7.96"/>
                    <measurement group_id="O2" value="4.25" lower_limit="2.77" upper_limit="6.58"/>
                    <measurement group_id="O3" value="3.87" lower_limit="2.49" upper_limit="6.02"/>
                    <measurement group_id="O4" value="6.65" lower_limit="4.32" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of immune responses of a TIVc-High Dose to TIVe, assessed in terms of vaccine group GMT ratios against influenza strain A/H1N1 at Day 1</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the Lower limit of the 2-sided 95% CI of the vaccine group GMT ratio ≥ 0.67</non_inferiority_desc>
            <param_type>Vaccine Group Ratios at Day 1</param_type>
            <param_value>1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>1.53</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of immune responses of a TIVc-High Dose to TIVe, assessed in terms of vaccine group GMT ratios against influenza strain A/H1N1 at Day 50</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the Lower limit of the 2-sided 95% CI of the vaccine group GMT ratio ≥ 0.67</non_inferiority_desc>
            <param_type>Vaccine Group ratios at Day 50</param_type>
            <param_value>2.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.34</ci_lower_limit>
            <ci_upper_limit>3.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of immune responses of a TIVc-High Dose to TIVe, assessed in terms of vaccine group GMT ratios against influenza strain A/H3N2 at Day 1</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the Lower limit of the 2-sided 95% CI of the vaccine group GMT ratio ≥ 0.67</non_inferiority_desc>
            <param_type>Vaccine Group ratios at Day 1</param_type>
            <param_value>0.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.43</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of immune responses of a TIVc-High Dose to TIVe, assessed in terms of vaccine group GMT ratios against influenza strain A/H3N2 at Day 50</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the Lower limit of the 2-sided 95% CI of the vaccine group GMT ratio ≥ 0.67</non_inferiority_desc>
            <param_type>Vaccine Group Ratios at Day 50</param_type>
            <param_value>0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.45</ci_lower_limit>
            <ci_upper_limit>0.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of immune responses of a TIVc-High Dose to TIVe, assessed in terms of vaccine group GMT ratios against influenza strain B at Day 1</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the Lower limit of the 2-sided 95% CI of the vaccine group GMT ratio ≥ 0.67</non_inferiority_desc>
            <param_type>Vaccine Group Ratios at Day 1</param_type>
            <param_value>1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.92</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of immune responses of a TIVc-High Dose to TIVe, assessed in terms of vaccine group GMT ratios against influenza strain B at Day 50</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the Lower limit of the 2-sided 95% CI of the vaccine group GMT ratio ≥ 0.67</non_inferiority_desc>
            <param_type>Vaccine Group ratios at Day 50</param_type>
            <param_value>0.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of immune responses of a TIVc-Full Dose to TIVe, assessed in terms of vaccine group GMT ratios against influenza strain A/H1N1 at Day 1</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the Lower limit of the 2-sided 95% CI of the vaccine group GMT ratio ≥ 0.67</non_inferiority_desc>
            <param_type>Vaccine Group Ratios at Day 1</param_type>
            <param_value>1.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>1.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of immune responses of a TIVc-Full Dose to TIVe, assessed in terms of vaccine group GMT ratios against influenza strain A/H1N1 at Day 50</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the Lower limit of the 2-sided 95% CI of the vaccine group GMT ratio ≥ 0.67</non_inferiority_desc>
            <param_type>Vaccine Group Ratios at Day 50</param_type>
            <param_value>1.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.2</ci_lower_limit>
            <ci_upper_limit>3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of immune responses of a TIVc-Full Dose to TIVe, assessed in terms of vaccine group GMT ratios against influenza strain A/H3N2 at Day 1</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the Lower limit of the 2-sided 95% CI of the vaccine group GMT ratio ≥ 0.67</non_inferiority_desc>
            <param_type>Vaccine Group Ratios at Day 1</param_type>
            <param_value>0.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.33</ci_lower_limit>
            <ci_upper_limit>0.81</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of immune responses of a TIVc-Full Dose to TIVe, assessed in terms of vaccine group GMT ratios against influenza strain A/H3N2 at Day 50</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the Lower limit of the 2-sided 95% CI of the vaccine group GMT ratio ≥ 0.67</non_inferiority_desc>
            <param_type>Vaccine Group Ratios at Day 50</param_type>
            <param_value>0.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.35</ci_lower_limit>
            <ci_upper_limit>0.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of immune responses of a TIVc-Full Dose to TIVe, assessed in terms of vaccine group GMT ratios against influenza strain B at Day 1</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the Lower limit of the 2-sided 95% CI of the vaccine group GMT ratio ≥ 0.67</non_inferiority_desc>
            <param_type>Vaccine Group ratios at Day 1</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of immune responses of a TIVc-Full Dose to TIVe, assessed in terms of vaccine group GMT ratios against influenza strain B at Day 50</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the Lower limit of the 2-sided 95% CI of the vaccine group GMT ratio ≥ 0.67</non_inferiority_desc>
            <param_type>Vaccine Group Ratios at Day 50</param_type>
            <param_value>0.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.47</ci_lower_limit>
            <ci_upper_limit>0.81</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of immune responses of a TIVc- Half Dose to TIVe, assessed in terms of vaccine group GMT ratios against influenza strain A/H1N1 at Day 1</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the Lower limit of the 2-sided 95% CI of the vaccine group GMT ratio ≥ 0.67</non_inferiority_desc>
            <param_type>Vaccine Group Ratios at Day 1</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>1.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of immune responses of a TIVc- Half Dose to TIVe, assessed in terms of vaccine group GMT ratios against influenza strain A/H1N1 at Day 50</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the Lower limit of the 2-sided 95% CI of the vaccine group GMT ratio ≥ 0.67</non_inferiority_desc>
            <param_type>Vaccine Group ratios at Day 50</param_type>
            <param_value>1.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.03</ci_lower_limit>
            <ci_upper_limit>2.61</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of immune responses of a TIVc- Half Dose to TIVe, assessed in terms of vaccine group GMT ratios against influenza strain A/H3N2 at Day 1</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the Lower limit of the 2-sided 95% CI of the vaccine group GMT ratio ≥ 0.67</non_inferiority_desc>
            <param_type>Vaccine Group Ratios at Day 1</param_type>
            <param_value>0.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.47</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of immune responses of a TIVc- Half Dose to TIVe, assessed in terms of vaccine group GMT ratios against influenza strain A/H3N2 at Day 50</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the Lower limit of the 2-sided 95% CI of the vaccine group GMT ratio ≥ 0.67</non_inferiority_desc>
            <param_type>Vaccine Group ratios at Day 50</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.3</ci_lower_limit>
            <ci_upper_limit>0.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of immune responses of a TIVc- Half Dose to TIVe, assessed in terms of vaccine group GMT ratios against influenza strain B at Day 1</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the Lower limit of the 2-sided 95% CI of the vaccine group GMT ratio ≥ 0.67</non_inferiority_desc>
            <param_type>Vaccine Group Ratios at Day 1</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of immune responses of a TIVc- Half Dose to TIVe, assessed in terms of vaccine group GMT ratios against influenza strain B at Day 50</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the Lower limit of the 2-sided 95% CI of the vaccine group GMT ratio ≥ 0.67</non_inferiority_desc>
            <param_type>Vaccine Group Ratios at Day 50</param_type>
            <param_value>0.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.42</ci_lower_limit>
            <ci_upper_limit>0.72</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentages of Subjects (6 to &lt;48 Months Old) Achieving Seroconversion or Significant Increase After Receiving Two Doses of Either TIVc or TIVe Vaccine</title>
        <description>Immunogenicity was assessed in terms number (%) of subjects (6 to &lt;48 months old) achieving seroconversion as measured by HI antibody titer, day 50 after vaccination with two doses of either TIVc or TIVe vaccine Seroconversion was defined as subjects with either a pre-vaccination (baseline) HI titer &lt; 1:10 and post-vaccination HI titer ≥ 1:40 or with a pre-vaccination HI titer ≥ 1:10 and a ≥ 4-fold increase in post-vaccination HI antibody titer</description>
        <time_frame>Day 50 post vaccination</time_frame>
        <population>Analysis was done on PP population</population>
        <group_list>
          <group group_id="O1">
            <title>TIVc-High Dose</title>
            <description>Subjects (6 to &lt;48 months old) received two doses of 0.75 mL of TIVc vaccine</description>
          </group>
          <group group_id="O2">
            <title>TIVc-Full Dose</title>
            <description>Subjects(6 to &lt;48 months old) received two doses of 0.50 mL of TIVc vaccine</description>
          </group>
          <group group_id="O3">
            <title>TIVc- Half Dose</title>
            <description>Subjects (6 to &lt;48 months old)received two doses of 0.25 mL of TIVc vaccine</description>
          </group>
          <group group_id="O4">
            <title>TIVe</title>
            <description>Subjects (6 to &lt;48 months old) received two doses of TIVe vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects (6 to &lt;48 Months Old) Achieving Seroconversion or Significant Increase After Receiving Two Doses of Either TIVc or TIVe Vaccine</title>
          <description>Immunogenicity was assessed in terms number (%) of subjects (6 to &lt;48 months old) achieving seroconversion as measured by HI antibody titer, day 50 after vaccination with two doses of either TIVc or TIVe vaccine Seroconversion was defined as subjects with either a pre-vaccination (baseline) HI titer &lt; 1:10 and post-vaccination HI titer ≥ 1:40 or with a pre-vaccination HI titer ≥ 1:10 and a ≥ 4-fold increase in post-vaccination HI antibody titer</description>
          <population>Analysis was done on PP population</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="147"/>
                <count group_id="O3" value="141"/>
                <count group_id="O4" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1_Day 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" lower_limit="77" upper_limit="89"/>
                    <measurement group_id="O2" value="81" lower_limit="74" upper_limit="87"/>
                    <measurement group_id="O3" value="79" lower_limit="72" upper_limit="86"/>
                    <measurement group_id="O4" value="74" lower_limit="66" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2_Day 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94" lower_limit="89" upper_limit="97"/>
                    <measurement group_id="O2" value="90" lower_limit="84" upper_limit="94"/>
                    <measurement group_id="O3" value="87" lower_limit="80" upper_limit="92"/>
                    <measurement group_id="O4" value="92" lower_limit="87" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B_Day 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69" lower_limit="61" upper_limit="76"/>
                    <measurement group_id="O2" value="69" lower_limit="61" upper_limit="77"/>
                    <measurement group_id="O3" value="62" lower_limit="54" upper_limit="70"/>
                    <measurement group_id="O4" value="80" lower_limit="73" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of immune responses of TIVc-High Dose to TIVe, assessed in terms of Vaccine Group Differences with seroconversion against influenza strain A/H1N1</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the Lower limit of the 2-sided 95% CI on the difference between seroconversion rates ≥ -10%</non_inferiority_desc>
            <param_type>Vaccine Group Differences</param_type>
            <param_value>10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0</ci_lower_limit>
            <ci_upper_limit>18.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of immune responses of TIVc-High Dose to TIVe, assessed in terms of Vaccine Group Differences with seroconversion against influenza strain A/H3N2</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the Lower limit of the 2-sided 95% CI on the difference between seroconversion rates ≥ -10%</non_inferiority_desc>
            <param_type>Vaccine Group Differences</param_type>
            <param_value>2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4</ci_lower_limit>
            <ci_upper_limit>8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of immune responses of TIVc-High Dose to TIVe, assessed in terms of Vaccine Group Differences with seroconversion against influenza strain B</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the Lower limit of the 2-sided 95% CI on the difference between seroconversion rates ≥ -10%</non_inferiority_desc>
            <param_type>Vaccine Group differences</param_type>
            <param_value>-11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.1</ci_lower_limit>
            <ci_upper_limit>-1.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of immune responses of TIVc-Full Dose to TIVe, assessed in terms of Vaccine Group Differences with seroconversion against influenza strain A/H1N1</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the Lower limit of the 2-sided 95% CI on the difference between seroconversion rates ≥ -10%</non_inferiority_desc>
            <param_type>Vaccine Group Differences</param_type>
            <param_value>7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.5</ci_lower_limit>
            <ci_upper_limit>16.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of immune responses of TIVc-Full Dose to TIVe, assessed in terms of Vaccine Group Differences with seroconversion against influenza strain A/H3N2</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the Lower limit of the 2-sided 95% CI on the difference between seroconversion rates ≥ -10%</non_inferiority_desc>
            <param_type>Vaccine Group differences</param_type>
            <param_value>-3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.5</ci_lower_limit>
            <ci_upper_limit>4.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of immune responses of TIVc-Full Dose to TIVe, assessed in terms of Vaccine Group Differences with seroconversion against influenza strain B</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the Lower limit of the 2-sided 95% CI on the difference between seroconversion rates ≥ -10%</non_inferiority_desc>
            <param_type>Vaccine Group Differences</param_type>
            <param_value>-11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-20.5</ci_lower_limit>
            <ci_upper_limit>-1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of immune responses of TIVc- Half Dose to TIVe, assessed in terms of Vaccine Group Differences with seroconversion against influenza strain A/H1N1</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the Lower limit of the 2-sided 95% CI on the difference between seroconversion rates ≥ -10%</non_inferiority_desc>
            <param_type>Vaccine Group Differences</param_type>
            <param_value>6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.2</ci_lower_limit>
            <ci_upper_limit>15.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of immune responses of TIVc- Half Dose to TIVe, assessed in terms of Vaccine Group Differences with seroconversion against influenza strain A/H3N2</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the Lower limit of the 2-sided 95% CI on the difference between seroconversion rates ≥ -10%</non_inferiority_desc>
            <param_type>Vaccine Group Differences</param_type>
            <param_value>-6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.4</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of immune responses of TIVc- Half Dose to TIVe, assessed in terms of Vaccine Group Differences with seroconversion against influenza strain B</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the Lower limit of the 2-sided 95% CI on the difference between seroconversion rates ≥ -10%</non_inferiority_desc>
            <param_type>Vaccine Group Differences</param_type>
            <param_value>-18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-27.8</ci_lower_limit>
            <ci_upper_limit>-7.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Desirability Index Score of Subjects (6 to &lt;48 Months Old) Reporting Severe Solicited Local and Systemic Reactions After Vaccination With Either TIVc or TIVe Vaccine</title>
        <description>Differences in percentages of subjects (6 to &lt;48 months old) with severe local solicited AEs and severe solicited systemic AEs, 3 days after vaccination with either TIVc or TIVe vaccine was assessed in terms of an individual desirability index score (High dose, Full dose, Half dose TIVc vs. TIVe vaccine). An individual desirability index score was assigned to each (non-transformed) safety value based on predefined functions. Each desirability index score is assigned a value between 0 and 1, wherein 0 is an undesirable response and 1 is a highly desirable response.</description>
        <time_frame>Day 1 to Day 3</time_frame>
        <population>Analysis was done on PPSd-All subjects in the FASd who:Correctly received the vaccine (i.e., received the vaccine to which the subjects is randomized and at the scheduled time points).</population>
        <group_list>
          <group group_id="O1">
            <title>TIVc-High Dose-TIVe</title>
            <description>Subjects (6 to &lt;48 months old) received two doses of 0.75 mL of TIVc vaccine vs Subjects (6 to &lt;48 months old) received two doses of TIVe vaccine</description>
          </group>
          <group group_id="O2">
            <title>TIVc-Full Dose-TIVe</title>
            <description>Subjects(6 to &lt;48 months old) received two doses of 0.50 mL of TIVc vaccine vs Subjects (6 to &lt;48 months old) received two doses of TIVe vaccine</description>
          </group>
          <group group_id="O3">
            <title>TIVc- Half Dose-TIVe</title>
            <description>Subjects (6 to &lt;48 months old)received two doses of 0.25 mL of TIVc vaccine vs Subjects (6 to &lt;48 months old) received two doses of TIVe vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Desirability Index Score of Subjects (6 to &lt;48 Months Old) Reporting Severe Solicited Local and Systemic Reactions After Vaccination With Either TIVc or TIVe Vaccine</title>
          <description>Differences in percentages of subjects (6 to &lt;48 months old) with severe local solicited AEs and severe solicited systemic AEs, 3 days after vaccination with either TIVc or TIVe vaccine was assessed in terms of an individual desirability index score (High dose, Full dose, Half dose TIVc vs. TIVe vaccine). An individual desirability index score was assigned to each (non-transformed) safety value based on predefined functions. Each desirability index score is assigned a value between 0 and 1, wherein 0 is an undesirable response and 1 is a highly desirable response.</description>
          <population>Analysis was done on PPSd-All subjects in the FASd who:Correctly received the vaccine (i.e., received the vaccine to which the subjects is randomized and at the scheduled time points).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
                <count group_id="O2" value="294"/>
                <count group_id="O3" value="291"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Severe solicited local AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000"/>
                    <measurement group_id="O2" value="0.000"/>
                    <measurement group_id="O3" value="0.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe solicited systemic AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.040"/>
                    <measurement group_id="O2" value="0.000"/>
                    <measurement group_id="O3" value="0.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Desirability Index Score</param_type>
            <param_value>0.000</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Desirability Score: If this difference is negative, then it is defined as non-desirable (D equal to 0), while if the difference is positive, then D will equal to the relative reduction calculated in the following way: D = (TIVe - TIVc Dose )/TIVe.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Desirability Index Score</param_type>
            <param_value>0.000</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Desirability Score: If this difference is negative, then it is defined as non-desirable (D equal to 0), while if the difference is positive, then D will equal to the relative reduction calculated in the following way: D = (TIVe - TIVc Dose )/TIVe.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Desirability Index Score</param_type>
            <param_value>0.000</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Desirability Score: If this difference is negative, then it is defined as non-desirable (D equal to 0), while if the difference is positive, then D will equal to the relative reduction calculated in the following way: D = (TIVe - TIVc Dose )/TIVe.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects (6 to &lt;48 Months Old) Achieving Seroconversion or Significant Increase After Receiving Two Doses of Either TIVc or TIVe Vaccine</title>
        <description>Immunogenicity was assessed in terms of number (%) of subjects (6 to &lt;48 months old) achieving seroconversion as measured by HI assay, day 50 after vaccination with two doses of either TIVc or TIVe vaccine
Seroconversion was defined as subjects with either a pre-vaccination (baseline) HI titer &lt; 1:10 and post-vaccination HI titer ≥ 1:40 or with a pre-vaccination HI titer ≥ 1:10 and a ≥ 4-fold increase in post-vaccination HI antibody titer
The Center for Biologics Evaluation, Research, and Review (CBER) criterion for pediatric population is that the lower bound of the two-sided 95% confidence interval (CI) for the percentage of subjects achieving seroconversion for HI antibody should meet or exceed 40%
The Committee for Medicinal Products for Human Use (CHMP) criterion for pediatric population is that the percentage of subjects achieving seroconversion or significant increase in HI antibody titers &gt;40%</description>
        <time_frame>Day 50 post vaccination</time_frame>
        <population>Analysis was done on Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>TIVc-High Dose</title>
            <description>Subjects (6 to &lt;48 months old) received two doses of 0.75 mL of TIVc vaccine</description>
          </group>
          <group group_id="O2">
            <title>TIVc-Full Dose</title>
            <description>Subjects(6 to &lt;48 months old) received two doses of 0.50 mL of TIVc vaccine</description>
          </group>
          <group group_id="O3">
            <title>TIVc- Half Dose</title>
            <description>Subjects (6 to &lt;48 months old)received two doses of 0.25 mL of TIVc vaccine</description>
          </group>
          <group group_id="O4">
            <title>TIVe</title>
            <description>Subjects (6 to &lt;48 months old) received two doses of TIVe vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects (6 to &lt;48 Months Old) Achieving Seroconversion or Significant Increase After Receiving Two Doses of Either TIVc or TIVe Vaccine</title>
          <description>Immunogenicity was assessed in terms of number (%) of subjects (6 to &lt;48 months old) achieving seroconversion as measured by HI assay, day 50 after vaccination with two doses of either TIVc or TIVe vaccine
Seroconversion was defined as subjects with either a pre-vaccination (baseline) HI titer &lt; 1:10 and post-vaccination HI titer ≥ 1:40 or with a pre-vaccination HI titer ≥ 1:10 and a ≥ 4-fold increase in post-vaccination HI antibody titer
The Center for Biologics Evaluation, Research, and Review (CBER) criterion for pediatric population is that the lower bound of the two-sided 95% confidence interval (CI) for the percentage of subjects achieving seroconversion for HI antibody should meet or exceed 40%
The Committee for Medicinal Products for Human Use (CHMP) criterion for pediatric population is that the percentage of subjects achieving seroconversion or significant increase in HI antibody titers &gt;40%</description>
          <population>Analysis was done on Full analysis set</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="164"/>
                <count group_id="O3" value="161"/>
                <count group_id="O4" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84" lower_limit="77" upper_limit="89"/>
                    <measurement group_id="O2" value="80" lower_limit="74" upper_limit="86"/>
                    <measurement group_id="O3" value="82" lower_limit="75" upper_limit="88"/>
                    <measurement group_id="O4" value="73" lower_limit="65" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94" lower_limit="89" upper_limit="97"/>
                    <measurement group_id="O2" value="91" lower_limit="85" upper_limit="95"/>
                    <measurement group_id="O3" value="88" lower_limit="81" upper_limit="92"/>
                    <measurement group_id="O4" value="93" lower_limit="88" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68" lower_limit="61" upper_limit="75"/>
                    <measurement group_id="O2" value="70" lower_limit="62" upper_limit="76"/>
                    <measurement group_id="O3" value="63" lower_limit="55" upper_limit="70"/>
                    <measurement group_id="O4" value="79" lower_limit="72" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects (6 to &lt;48 Months Old) Achieving HI Titer ≥1:40 After Receiving Two Doses of Either TIVc or TIVe Vaccine</title>
        <description>Immunogenicity was assessed in terms of number (%) of subjects (6 to &lt;48 months old) achieving HI titer ≥1:40 as measured by HI assay, day 50 after vaccination with two doses of either TIVc or TIVe vaccine
The CBER criterion for pediatric population is that the lower bound of the two-sided 95% CI for the percentage of subjects achieving an HI antibody titer ≥1:40 should meet or exceed 70%
The CHMP criterion for pediatric population is that the percentage of subjects achieving HI antibody titers ≥1:40 should be &gt;70%</description>
        <time_frame>Day 1, Day 50 post vaccination</time_frame>
        <population>Analysis was done on FAS</population>
        <group_list>
          <group group_id="O1">
            <title>TIVc-High Dose</title>
            <description>Subjects (6 to &lt;48 months old) received two doses of 0.75 mL of TIVc vaccine</description>
          </group>
          <group group_id="O2">
            <title>TIVc-Full Dose</title>
            <description>Subjects(6 to &lt;48 months old) received two doses of 0.50 mL of TIVc vaccine</description>
          </group>
          <group group_id="O3">
            <title>TIVc- Half Dose</title>
            <description>Subjects (6 to &lt;48 months old)received two doses of 0.25 mL of TIVc vaccine</description>
          </group>
          <group group_id="O4">
            <title>TIVe</title>
            <description>Subjects (6 to &lt;48 months old) received two doses of TIVe vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects (6 to &lt;48 Months Old) Achieving HI Titer ≥1:40 After Receiving Two Doses of Either TIVc or TIVe Vaccine</title>
          <description>Immunogenicity was assessed in terms of number (%) of subjects (6 to &lt;48 months old) achieving HI titer ≥1:40 as measured by HI assay, day 50 after vaccination with two doses of either TIVc or TIVe vaccine
The CBER criterion for pediatric population is that the lower bound of the two-sided 95% CI for the percentage of subjects achieving an HI antibody titer ≥1:40 should meet or exceed 70%
The CHMP criterion for pediatric population is that the percentage of subjects achieving HI antibody titers ≥1:40 should be &gt;70%</description>
          <population>Analysis was done on FAS</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="164"/>
                <count group_id="O3" value="161"/>
                <count group_id="O4" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1: Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26" lower_limit="20" upper_limit="34"/>
                    <measurement group_id="O2" value="32" lower_limit="25" upper_limit="39"/>
                    <measurement group_id="O3" value="29" lower_limit="22" upper_limit="37"/>
                    <measurement group_id="O4" value="26" lower_limit="20" upper_limit="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1: Day 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86" lower_limit="80" upper_limit="91"/>
                    <measurement group_id="O2" value="85" lower_limit="78" upper_limit="90"/>
                    <measurement group_id="O3" value="86" lower_limit="79" upper_limit="91"/>
                    <measurement group_id="O4" value="77" lower_limit="69" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2: Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45" lower_limit="37" upper_limit="53"/>
                    <measurement group_id="O2" value="40" lower_limit="33" upper_limit="48"/>
                    <measurement group_id="O3" value="48" lower_limit="41" upper_limit="56"/>
                    <measurement group_id="O4" value="52" lower_limit="44" upper_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2: Day 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="95" upper_limit="100"/>
                    <measurement group_id="O2" value="98" lower_limit="94" upper_limit="99"/>
                    <measurement group_id="O3" value="97" lower_limit="93" upper_limit="99"/>
                    <measurement group_id="O4" value="99" lower_limit="97" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B: Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="0" upper_limit="5"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O3" value="1" lower_limit="0.016" upper_limit="3"/>
                    <measurement group_id="O4" value="3" lower_limit="1" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B: Day 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69" lower_limit="61" upper_limit="76"/>
                    <measurement group_id="O2" value="70" lower_limit="62" upper_limit="76"/>
                    <measurement group_id="O3" value="63" lower_limit="55" upper_limit="70"/>
                    <measurement group_id="O4" value="80" lower_limit="73" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Ratios (GMR) in Subjects (6 to &lt;48 Months Old) After Receiving Two Doses of Either TIVc or TIVe Vaccine</title>
        <description>Immunogenicity was assessed in terms of GMR in subjects (6 to &lt;48 months old) as measured by HI assay, day 50 after vaccination with two doses of either TIVc or TIVe vaccine
The CHMP criterion is mean geometric ratio (GMR) &gt;2.5</description>
        <time_frame>Day 50 post vaccination over day 1</time_frame>
        <population>Analysis was done on FAS</population>
        <group_list>
          <group group_id="O1">
            <title>TIVc-High Dose</title>
            <description>Subjects (6 to &lt;48 months old) received two doses of 0.75 mL of TIVc vaccine</description>
          </group>
          <group group_id="O2">
            <title>TIVc-Full Dose</title>
            <description>Subjects(6 to &lt;48 months old) received two doses of 0.50 mL of TIVc vaccine</description>
          </group>
          <group group_id="O3">
            <title>TIVc- Half Dose</title>
            <description>Subjects (6 to &lt;48 months old)received two doses of 0.25 mL of TIVc vaccine</description>
          </group>
          <group group_id="O4">
            <title>TIVe</title>
            <description>Subjects (6 to &lt;48 months old) received two doses of TIVe vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Ratios (GMR) in Subjects (6 to &lt;48 Months Old) After Receiving Two Doses of Either TIVc or TIVe Vaccine</title>
          <description>Immunogenicity was assessed in terms of GMR in subjects (6 to &lt;48 months old) as measured by HI assay, day 50 after vaccination with two doses of either TIVc or TIVe vaccine
The CHMP criterion is mean geometric ratio (GMR) &gt;2.5</description>
          <population>Analysis was done on FAS</population>
          <units>Ratios</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="164"/>
                <count group_id="O3" value="161"/>
                <count group_id="O4" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="7.05" upper_limit="19"/>
                    <measurement group_id="O2" value="8.58" lower_limit="5.08" upper_limit="14"/>
                    <measurement group_id="O3" value="8.94" lower_limit="5.28" upper_limit="15"/>
                    <measurement group_id="O4" value="5.14" lower_limit="3.04" upper_limit="8.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="7.83" upper_limit="19"/>
                    <measurement group_id="O2" value="13" lower_limit="8.05" upper_limit="20"/>
                    <measurement group_id="O3" value="7.68" lower_limit="4.91" upper_limit="12"/>
                    <measurement group_id="O4" value="14" lower_limit="8.83" upper_limit="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.14" lower_limit="4.27" upper_limit="8.84"/>
                    <measurement group_id="O2" value="5.29" lower_limit="3.64" upper_limit="7.7"/>
                    <measurement group_id="O3" value="4.72" lower_limit="3.24" upper_limit="6.88"/>
                    <measurement group_id="O4" value="7.57" lower_limit="5.21" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Ratios (GMR) in Subjects (6 to &lt;48 Months Old) After Receiving Two Doses of Either TIVc or TIVe Vaccine</title>
        <description>Immunogenicity was assessed in terms of GMR in subjects (6 to &lt;48 months old) as measured by MN assay, day 50 after vaccination with two doses of either TIVc or TIVe vaccine</description>
        <time_frame>Day 50 post vaccination over day 1</time_frame>
        <population>Analysis was done on PPS</population>
        <group_list>
          <group group_id="O1">
            <title>TIVc-High Dose</title>
            <description>Subjects (6 to &lt;48 months old) received two doses of 0.75 mL of TIVc vaccine</description>
          </group>
          <group group_id="O2">
            <title>TIVc-Full Dose</title>
            <description>Subjects(6 to &lt;48 months old) received two doses of 0.50 mL of TIVc vaccine</description>
          </group>
          <group group_id="O3">
            <title>TIVc- Half Dose</title>
            <description>Subjects (6 to &lt;48 months old)received two doses of 0.25 mL of TIVc vaccine</description>
          </group>
          <group group_id="O4">
            <title>TIVe</title>
            <description>Subjects (6 to &lt;48 months old) received two doses of TIVe vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Ratios (GMR) in Subjects (6 to &lt;48 Months Old) After Receiving Two Doses of Either TIVc or TIVe Vaccine</title>
          <description>Immunogenicity was assessed in terms of GMR in subjects (6 to &lt;48 months old) as measured by MN assay, day 50 after vaccination with two doses of either TIVc or TIVe vaccine</description>
          <population>Analysis was done on PPS</population>
          <units>Ratios</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="148"/>
                <count group_id="O3" value="141"/>
                <count group_id="O4" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.84" lower_limit="4.29" upper_limit="14.33"/>
                    <measurement group_id="O2" value="5.81" lower_limit="3.17" upper_limit="10.65"/>
                    <measurement group_id="O3" value="5.98" lower_limit="3.22" upper_limit="11.09"/>
                    <measurement group_id="O4" value="17.82" lower_limit="9.73" upper_limit="32.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4" lower_limit="5" upper_limit="14.12"/>
                    <measurement group_id="O2" value="8.97" lower_limit="5.32" upper_limit="15.12"/>
                    <measurement group_id="O3" value="5.58" lower_limit="3.28" upper_limit="9.51"/>
                    <measurement group_id="O4" value="8.9" lower_limit="5.28" upper_limit="14.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.78" lower_limit="8.09" upper_limit="20.2"/>
                    <measurement group_id="O2" value="10.43" lower_limit="6.58" upper_limit="16.52"/>
                    <measurement group_id="O3" value="9.99" lower_limit="6.25" upper_limit="15.99"/>
                    <measurement group_id="O4" value="17.55" lower_limit="11.08" upper_limit="27.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects (6 to &lt;48 Months Old) With High Post Vaccination HI Titers (i.e. HI Titers ≥1:110, ≥1:150, ≥1:330 and ≥1:629) After Receiving Two Doses of Either TIVc or TIVe Vaccine</title>
        <description>Immunogenicity was assessed in terms of number (%) of subjects (6 to &lt;48 months old) achieving post vaccination HI titers (i.e. HI titers ≥1:110, ≥1:150, ≥1:330 and ≥1:629) as measured by HI assay, day 50 after vaccination with two doses of either TIVc or TIVe vaccine</description>
        <time_frame>Day 1 and Day 50 post vaccination</time_frame>
        <population>Analysis was done on PPS</population>
        <group_list>
          <group group_id="O1">
            <title>TIVc-High Dose</title>
            <description>Subjects (6 to &lt;48 months old) received two doses of 0.75 mL of TIVc vaccine</description>
          </group>
          <group group_id="O2">
            <title>TIVc-Full Dose</title>
            <description>Subjects(6 to &lt;48 months old) received two doses of 0.50 mL of TIVc vaccine</description>
          </group>
          <group group_id="O3">
            <title>TIVc- Half Dose</title>
            <description>Subjects (6 to &lt;48 months old)received two doses of 0.25 mL of TIVc vaccine</description>
          </group>
          <group group_id="O4">
            <title>TIVe</title>
            <description>Subjects (6 to &lt;48 months old) received two doses of TIVe vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects (6 to &lt;48 Months Old) With High Post Vaccination HI Titers (i.e. HI Titers ≥1:110, ≥1:150, ≥1:330 and ≥1:629) After Receiving Two Doses of Either TIVc or TIVe Vaccine</title>
          <description>Immunogenicity was assessed in terms of number (%) of subjects (6 to &lt;48 months old) achieving post vaccination HI titers (i.e. HI titers ≥1:110, ≥1:150, ≥1:330 and ≥1:629) as measured by HI assay, day 50 after vaccination with two doses of either TIVc or TIVe vaccine</description>
          <population>Analysis was done on PPS</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="147"/>
                <count group_id="O3" value="141"/>
                <count group_id="O4" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1: Day 1: HI titers ≥1:110</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26" lower_limit="19" upper_limit="33"/>
                    <measurement group_id="O2" value="31" lower_limit="24" upper_limit="39"/>
                    <measurement group_id="O3" value="26" lower_limit="19" upper_limit="34"/>
                    <measurement group_id="O4" value="26" lower_limit="19" upper_limit="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1: Day 50: HI titers ≥1:110</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78" lower_limit="70" upper_limit="84"/>
                    <measurement group_id="O2" value="80" lower_limit="72" upper_limit="86"/>
                    <measurement group_id="O3" value="71" lower_limit="63" upper_limit="78"/>
                    <measurement group_id="O4" value="59" lower_limit="51" upper_limit="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2: Day 1: HI titers ≥1:110</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40" lower_limit="33" upper_limit="49"/>
                    <measurement group_id="O2" value="37" lower_limit="29" upper_limit="45"/>
                    <measurement group_id="O3" value="43" lower_limit="34" upper_limit="51"/>
                    <measurement group_id="O4" value="47" lower_limit="39" upper_limit="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2: Day 50: HI titers ≥1:110</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88" lower_limit="82" upper_limit="93"/>
                    <measurement group_id="O2" value="86" lower_limit="80" upper_limit="91"/>
                    <measurement group_id="O3" value="82" lower_limit="74" upper_limit="88"/>
                    <measurement group_id="O4" value="97" lower_limit="93" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B: Day 1: HI titers ≥1:110</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0.016" upper_limit="4"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B: Day 50: HI titers ≥1:110</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40" lower_limit="33" upper_limit="49"/>
                    <measurement group_id="O2" value="30" lower_limit="23" upper_limit="38"/>
                    <measurement group_id="O3" value="24" lower_limit="17" upper_limit="32"/>
                    <measurement group_id="O4" value="39" lower_limit="31" upper_limit="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1: Day 1: HI titers ≥1:151</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" lower_limit="18" upper_limit="33"/>
                    <measurement group_id="O2" value="30" lower_limit="23" upper_limit="38"/>
                    <measurement group_id="O3" value="26" lower_limit="19" upper_limit="34"/>
                    <measurement group_id="O4" value="25" lower_limit="18" upper_limit="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1: Day 50: HI titers ≥1:151</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76" lower_limit="69" upper_limit="83"/>
                    <measurement group_id="O2" value="76" lower_limit="68" upper_limit="83"/>
                    <measurement group_id="O3" value="70" lower_limit="62" upper_limit="78"/>
                    <measurement group_id="O4" value="58" lower_limit="49" upper_limit="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2: Day 1: HI titers ≥1:151</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40" lower_limit="33" upper_limit="49"/>
                    <measurement group_id="O2" value="37" lower_limit="29" upper_limit="45"/>
                    <measurement group_id="O3" value="43" lower_limit="34" upper_limit="51"/>
                    <measurement group_id="O4" value="47" lower_limit="39" upper_limit="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2: Day 50: HI titers ≥1:150</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88" lower_limit="82" upper_limit="93"/>
                    <measurement group_id="O2" value="86" lower_limit="80" upper_limit="91"/>
                    <measurement group_id="O3" value="81" lower_limit="73" upper_limit="87"/>
                    <measurement group_id="O4" value="97" lower_limit="93" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B: Day 1: HI titers ≥1:151</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B: Day 50: HI titers ≥1:151</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40" lower_limit="32" upper_limit="48"/>
                    <measurement group_id="O2" value="30" lower_limit="23" upper_limit="38"/>
                    <measurement group_id="O3" value="23" lower_limit="17" upper_limit="31"/>
                    <measurement group_id="O4" value="39" lower_limit="31" upper_limit="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1: Day 1: HI titers ≥1:330</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="7" upper_limit="18"/>
                    <measurement group_id="O2" value="14" lower_limit="9" upper_limit="21"/>
                    <measurement group_id="O3" value="11" lower_limit="7" upper_limit="18"/>
                    <measurement group_id="O4" value="11" lower_limit="6" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1: Day 50: HI titers ≥1:330</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51" lower_limit="43" upper_limit="59"/>
                    <measurement group_id="O2" value="50" lower_limit="42" upper_limit="59"/>
                    <measurement group_id="O3" value="43" lower_limit="35" upper_limit="52"/>
                    <measurement group_id="O4" value="34" lower_limit="26" upper_limit="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2: Day 1: HI titers ≥1:330</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="11" upper_limit="23"/>
                    <measurement group_id="O2" value="12" lower_limit="7" upper_limit="18"/>
                    <measurement group_id="O3" value="13" lower_limit="8" upper_limit="19"/>
                    <measurement group_id="O4" value="21" lower_limit="15" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2: Day 50: HI titers ≥1:330</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62" lower_limit="53" upper_limit="69"/>
                    <measurement group_id="O2" value="56" lower_limit="48" upper_limit="65"/>
                    <measurement group_id="O3" value="52" lower_limit="43" upper_limit="60"/>
                    <measurement group_id="O4" value="68" lower_limit="59" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B: Day 1: HI titers ≥1:330</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B: Day 50: HI titers ≥1:330</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="2" upper_limit="9"/>
                    <measurement group_id="O2" value="4" lower_limit="2" upper_limit="9"/>
                    <measurement group_id="O3" value="3" lower_limit="1" upper_limit="7"/>
                    <measurement group_id="O4" value="8" lower_limit="4" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1: Day 1: HI titers ≥1:629</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="5" upper_limit="15"/>
                    <measurement group_id="O2" value="12" lower_limit="7" upper_limit="18"/>
                    <measurement group_id="O3" value="11" lower_limit="6" upper_limit="17"/>
                    <measurement group_id="O4" value="8" lower_limit="4" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1: Day 50: HI titers ≥1:629</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48" lower_limit="40" upper_limit="56"/>
                    <measurement group_id="O2" value="47" lower_limit="39" upper_limit="55"/>
                    <measurement group_id="O3" value="43" lower_limit="35" upper_limit="52"/>
                    <measurement group_id="O4" value="33" lower_limit="26" upper_limit="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2: Day 1: HI titers ≥1:629</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="11" upper_limit="23"/>
                    <measurement group_id="O2" value="12" lower_limit="7" upper_limit="18"/>
                    <measurement group_id="O3" value="12" lower_limit="7" upper_limit="19"/>
                    <measurement group_id="O4" value="21" lower_limit="15" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2: Day 50: HI titers ≥1:629</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62" lower_limit="53" upper_limit="69"/>
                    <measurement group_id="O2" value="56" lower_limit="47" upper_limit="64"/>
                    <measurement group_id="O3" value="52" lower_limit="43" upper_limit="60"/>
                    <measurement group_id="O4" value="68" lower_limit="59" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B: Day 1: HI titers ≥1:629</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B: Day 50: HI titers ≥1:629</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="2" upper_limit="9"/>
                    <measurement group_id="O2" value="3" lower_limit="1" upper_limit="8"/>
                    <measurement group_id="O3" value="3" lower_limit="1" upper_limit="7"/>
                    <measurement group_id="O4" value="7" lower_limit="3" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects (6 to &lt;48 Months Old) Achieving MN Titer ≥1:20 After Receiving Two Doses of Either TIVc or TIVe Vaccine</title>
        <description>Immunogenicity was assessed in terms of number (%) of subjects (6 to &lt;48 months old) achieving MN titer ≥1:20 as measured by MN assay, day 50 after vaccination with two doses of either TIVc or TIVe vaccine
Post-vaccination MN titer ≥1:20 was defined as for subjects with baseline (day 1) MN titer &lt;1:10, or a minimum 2-fold increase in titer on day 50 for subjects with baseline titer ≥1:10 and corresponding 95% CI</description>
        <time_frame>Day 1 and Day 50 post vaccination</time_frame>
        <population>Analysis was done on PPS</population>
        <group_list>
          <group group_id="O1">
            <title>TIVc-High Dose</title>
            <description>Subjects (6 to &lt;48 months old) received two doses of 0.75 mL of TIVc vaccine</description>
          </group>
          <group group_id="O2">
            <title>TIVc-Full Dose</title>
            <description>Subjects(6 to &lt;48 months old) received two doses of 0.50 mL of TIVc vaccine</description>
          </group>
          <group group_id="O3">
            <title>TIVc- Half Dose</title>
            <description>Subjects (6 to &lt;48 months old)received two doses of 0.25 mL of TIVc vaccine</description>
          </group>
          <group group_id="O4">
            <title>TIVe</title>
            <description>Subjects (6 to &lt;48 months old) received two doses of TIVe vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects (6 to &lt;48 Months Old) Achieving MN Titer ≥1:20 After Receiving Two Doses of Either TIVc or TIVe Vaccine</title>
          <description>Immunogenicity was assessed in terms of number (%) of subjects (6 to &lt;48 months old) achieving MN titer ≥1:20 as measured by MN assay, day 50 after vaccination with two doses of either TIVc or TIVe vaccine
Post-vaccination MN titer ≥1:20 was defined as for subjects with baseline (day 1) MN titer &lt;1:10, or a minimum 2-fold increase in titer on day 50 for subjects with baseline titer ≥1:10 and corresponding 95% CI</description>
          <population>Analysis was done on PPS</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="148"/>
                <count group_id="O3" value="141"/>
                <count group_id="O4" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94" lower_limit="89" upper_limit="97"/>
                    <measurement group_id="O2" value="93" lower_limit="88" upper_limit="97"/>
                    <measurement group_id="O3" value="91" lower_limit="86" upper_limit="96"/>
                    <measurement group_id="O4" value="97" lower_limit="93" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="90" upper_limit="98"/>
                    <measurement group_id="O2" value="94" lower_limit="89" upper_limit="97"/>
                    <measurement group_id="O3" value="94" lower_limit="89" upper_limit="98"/>
                    <measurement group_id="O4" value="94" lower_limit="89" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" lower_limit="86" upper_limit="95"/>
                    <measurement group_id="O2" value="92" lower_limit="86" upper_limit="96"/>
                    <measurement group_id="O3" value="93" lower_limit="87" upper_limit="97"/>
                    <measurement group_id="O4" value="97" lower_limit="93" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects (6 to &lt;48 Months Old) Achieving MN Titer ≥1:40 After Receiving Two Doses of Either TIVc or TIVe Vaccine</title>
        <description>Immunogenicity was assessed in terms of number (%) of subjects (6 to &lt;48 months old) achieving MN titer ≥1:40 as measured by MN assay, day 50 after vaccination with two doses of either TIVc or TIVe vaccine
Post-vaccination MN titer ≥1:40 was defined as for subjects with baseline (day 1) MN titer &lt;1:10, or a minimum 4-fold increase in titer on day 50 for subjects with baseline titer ≥1:10 and corresponding 95% CI</description>
        <time_frame>Day 1 and Day 50 post vaccination</time_frame>
        <population>Analysis was done on PPS</population>
        <group_list>
          <group group_id="O1">
            <title>TIVc-High Dose</title>
            <description>Subjects (6 to &lt;48 months old) received two doses of 0.75 mL of TIVc vaccine</description>
          </group>
          <group group_id="O2">
            <title>TIVc-Full Dose</title>
            <description>Subjects(6 to &lt;48 months old) received two doses of 0.50 mL of TIVc vaccine</description>
          </group>
          <group group_id="O3">
            <title>TIVc- Half Dose</title>
            <description>Subjects (6 to &lt;48 months old)received two doses of 0.25 mL of TIVc vaccine</description>
          </group>
          <group group_id="O4">
            <title>TIVe</title>
            <description>Subjects (6 to &lt;48 months old) received two doses of TIVe vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects (6 to &lt;48 Months Old) Achieving MN Titer ≥1:40 After Receiving Two Doses of Either TIVc or TIVe Vaccine</title>
          <description>Immunogenicity was assessed in terms of number (%) of subjects (6 to &lt;48 months old) achieving MN titer ≥1:40 as measured by MN assay, day 50 after vaccination with two doses of either TIVc or TIVe vaccine
Post-vaccination MN titer ≥1:40 was defined as for subjects with baseline (day 1) MN titer &lt;1:10, or a minimum 4-fold increase in titer on day 50 for subjects with baseline titer ≥1:10 and corresponding 95% CI</description>
          <population>Analysis was done on PPS</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="148"/>
                <count group_id="O3" value="141"/>
                <count group_id="O4" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87" lower_limit="80" upper_limit="91"/>
                    <measurement group_id="O2" value="89" lower_limit="82" upper_limit="93"/>
                    <measurement group_id="O3" value="84" lower_limit="77" upper_limit="90"/>
                    <measurement group_id="O4" value="95" lower_limit="90" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85" lower_limit="79" upper_limit="90"/>
                    <measurement group_id="O2" value="85" lower_limit="78" upper_limit="90"/>
                    <measurement group_id="O3" value="82" lower_limit="74" upper_limit="88"/>
                    <measurement group_id="O4" value="80" lower_limit="73" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" lower_limit="76" upper_limit="88"/>
                    <measurement group_id="O2" value="87" lower_limit="81" upper_limit="92"/>
                    <measurement group_id="O3" value="83" lower_limit="76" upper_limit="89"/>
                    <measurement group_id="O4" value="96" lower_limit="91" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects (6 to &lt;48 Months Old) Reporting Solicited Local (Grading Type I) and Systemic Adverse Events (AEs) After Two Doses of Either TIVc or TIVe Vaccine</title>
        <description>Safety was assessed in terms of number of subjects (6 to &lt;48 months old) reporting solicited local and systemic reactions, day 1 to day 7 after vaccination with two doses of either TIVc or TIVe vaccine (By Any Vaccination)</description>
        <time_frame>Day 1 to Day 7</time_frame>
        <population>Analyses was done on solicited safety data set. 4 subjects (3 subjects from the TIVe group, and 1 subject from the full dose TIVc group, were excluded from the solicited safety set analyses (6h –day3, day4-day7 and 6h – day 7) as these subjects did not provide any post vaccination solicited safety data</population>
        <group_list>
          <group group_id="O1">
            <title>TIVc-High Dose</title>
            <description>Subjects (6 to &lt;48 months old) received two doses of 0.75 mL of TIVc vaccine</description>
          </group>
          <group group_id="O2">
            <title>TIVc-Full Dose</title>
            <description>Subjects(6 to &lt;48 months old) received two doses of 0.50 mL of TIVc vaccine</description>
          </group>
          <group group_id="O3">
            <title>TIVc- Half Dose</title>
            <description>Subjects (6 to &lt;48 months old)received two doses of 0.25 mL of TIVc vaccine</description>
          </group>
          <group group_id="O4">
            <title>TIVe</title>
            <description>Subjects (6 to &lt;48 months old) received two doses of TIVe vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects (6 to &lt;48 Months Old) Reporting Solicited Local (Grading Type I) and Systemic Adverse Events (AEs) After Two Doses of Either TIVc or TIVe Vaccine</title>
          <description>Safety was assessed in terms of number of subjects (6 to &lt;48 months old) reporting solicited local and systemic reactions, day 1 to day 7 after vaccination with two doses of either TIVc or TIVe vaccine (By Any Vaccination)</description>
          <population>Analyses was done on solicited safety data set. 4 subjects (3 subjects from the TIVe group, and 1 subject from the full dose TIVc group, were excluded from the solicited safety set analyses (6h –day3, day4-day7 and 6h – day 7) as these subjects did not provide any post vaccination solicited safety data</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="174"/>
                <count group_id="O2" value="165"/>
                <count group_id="O3" value="167"/>
                <count group_id="O4" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any local AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="56"/>
                    <measurement group_id="O3" value="60"/>
                    <measurement group_id="O4" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site tenderness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site ecchymosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Systemic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="72"/>
                    <measurement group_id="O3" value="69"/>
                    <measurement group_id="O4" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in eating habits</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="28"/>
                    <measurement group_id="O4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (≥ 38°C )</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prophylactic use of antipyretics/analgesics</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Therapeutic use of antipyretics/analgesics</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects (6 to &lt;48 Months Old) Reporting Unsolicited Adverse Events (AEs) After Two Doses of Either TIVc or TIVe Vaccine</title>
        <description>Safety was assessed in terms of number of subjects (6 to &lt;48 months old) reporting unsolicited reactions after Each /any Vaccination from Day 1 [Post Vaccination] to Day 29 [Pre Clinic Visit] and Day 29 [Post Vaccination] to Day 50 [Pre Clinic Visit] , Serious Adverse Events (SAEs), AEs leading to New Onset of Chronic Diseases (NOCD), AEs leading to withdrawal from the study and concomitant medications (day 1 to day 209) after vaccination with two doses of either TIVc or TIVe vaccine (By Any Vaccination)</description>
        <time_frame>Unsolicited AEs after Each/any Vaccination from Day 1 to Day 29 and Day 29 to Day 50 , Day 1 to Day 209</time_frame>
        <population>Analyses was done on unsolicited safety data set i.e. all subjects in the exposed set who have post-vaccination unsolicited AE data</population>
        <group_list>
          <group group_id="O1">
            <title>TIVc-High Dose</title>
            <description>Subjects (6 to &lt;48 months old) received two doses of 0.75 mL of TIVc vaccine</description>
          </group>
          <group group_id="O2">
            <title>TIVc-Full Dose</title>
            <description>Subjects(6 to &lt;48 months old) received two doses of 0.50 mL of TIVc vaccine</description>
          </group>
          <group group_id="O3">
            <title>TIVc- Half Dose</title>
            <description>Subjects (6 to &lt;48 months old)received two doses of 0.25 mL of TIVc vaccine</description>
          </group>
          <group group_id="O4">
            <title>TIVe</title>
            <description>Subjects (6 to &lt;48 months old) received two doses of TIVe vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects (6 to &lt;48 Months Old) Reporting Unsolicited Adverse Events (AEs) After Two Doses of Either TIVc or TIVe Vaccine</title>
          <description>Safety was assessed in terms of number of subjects (6 to &lt;48 months old) reporting unsolicited reactions after Each /any Vaccination from Day 1 [Post Vaccination] to Day 29 [Pre Clinic Visit] and Day 29 [Post Vaccination] to Day 50 [Pre Clinic Visit] , Serious Adverse Events (SAEs), AEs leading to New Onset of Chronic Diseases (NOCD), AEs leading to withdrawal from the study and concomitant medications (day 1 to day 209) after vaccination with two doses of either TIVc or TIVe vaccine (By Any Vaccination)</description>
          <population>Analyses was done on unsolicited safety data set i.e. all subjects in the exposed set who have post-vaccination unsolicited AE data</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="174"/>
                <count group_id="O2" value="166"/>
                <count group_id="O3" value="167"/>
                <count group_id="O4" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AEs(after any vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                    <measurement group_id="O2" value="107"/>
                    <measurement group_id="O3" value="91"/>
                    <measurement group_id="O4" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Possibly/probably related AEs (after any vaccin.)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="43"/>
                    <measurement group_id="O4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any AEs(after vaccination 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                    <measurement group_id="O2" value="84"/>
                    <measurement group_id="O3" value="69"/>
                    <measurement group_id="O4" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any AEs(after vaccination 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="64"/>
                    <measurement group_id="O3" value="50"/>
                    <measurement group_id="O4" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Possibly/probably related AEs (after vaccination 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="31"/>
                    <measurement group_id="O4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Possibly/probably related AEs (after vaccination 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any possibly/probably related SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any AE leading to premature withdrawal from study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New onset of chronic disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Throughout the study period, up to day 209 post vaccination.</time_frame>
      <desc>Solicited AEs were collected from day 1 to day 7 post vaccination, unsolicited AEs were collected from day 1 to day 50 post vaccination and SAEs -collected from day 1 to day 209 post vaccination.
A systematic adverse event is equivalent to an event that was solicited by the diary card, whereas a non-systematic event is an unsolicited adverse event</desc>
      <group_list>
        <group group_id="E1">
          <title>TIVc-High Dose</title>
          <description>Subjects (6 to &lt;48 months old) received two doses of 0.75 mL of TIVc vaccine</description>
        </group>
        <group group_id="E2">
          <title>TIVc-Full Dose</title>
          <description>Subjects(6 to &lt;48 months old) received two doses of 0.50 mL of TIVc vaccine</description>
        </group>
        <group group_id="E3">
          <title>TIVc- Half Dose</title>
          <description>Subjects (6 to &lt;48 months old)received two doses of 0.25 mL of TIVc vaccine</description>
        </group>
        <group group_id="E4">
          <title>TIVe</title>
          <description>Subjects (6 to &lt;48 months old) received two doses of TIVe vaccine</description>
        </group>
        <group group_id="E5">
          <title>Total</title>
          <description>Total number of subjects</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="164"/>
                <counts group_id="E5" subjects_affected="28" subjects_at_risk="671"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="671"/>
              </event>
              <event>
                <sub_title>INGUINAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="671"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="671"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="671"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="671"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="671"/>
              </event>
              <event>
                <sub_title>VARICELLA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="671"/>
              </event>
              <event>
                <sub_title>ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="671"/>
              </event>
              <event>
                <sub_title>AMOEBIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="671"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="671"/>
              </event>
              <event>
                <sub_title>HAND-FOOT-AND-MOUTH DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="671"/>
              </event>
              <event>
                <sub_title>PERIORBITAL CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="671"/>
              </event>
              <event>
                <sub_title>PHARYNGOTONSILLITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="671"/>
              </event>
              <event>
                <sub_title>PSEUDOMONAL SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="671"/>
              </event>
              <event>
                <sub_title>SUBCUTANEOUS ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="671"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="671"/>
              </event>
              <event>
                <sub_title>VIRAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="671"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ANIMAL BITE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="671"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>FEBRILE CONVULSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="164"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="671"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="671"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>URTICARIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="671"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="142" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="133" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="141" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="127" subjects_at_risk="164"/>
                <counts group_id="E5" subjects_affected="543" subjects_at_risk="671"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="164"/>
                <counts group_id="E5" subjects_affected="130" subjects_at_risk="671"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="164"/>
                <counts group_id="E5" subjects_affected="77" subjects_at_risk="671"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>INFLUENZA LIKE ILLNESS</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="164"/>
                <counts group_id="E5" subjects_affected="130" subjects_at_risk="671"/>
              </event>
              <event>
                <sub_title>INJECTION SITE ERYTHEMA</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="164"/>
                <counts group_id="E5" subjects_affected="127" subjects_at_risk="671"/>
              </event>
              <event>
                <sub_title>INJECTION SITE HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="164"/>
                <counts group_id="E5" subjects_affected="34" subjects_at_risk="671"/>
              </event>
              <event>
                <sub_title>INJECTION SITE INDURATION</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="164"/>
                <counts group_id="E5" subjects_affected="51" subjects_at_risk="671"/>
              </event>
              <event>
                <sub_title>INJECTION SITE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="47" subjects_at_risk="164"/>
                <counts group_id="E5" subjects_affected="198" subjects_at_risk="671"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="164"/>
                <counts group_id="E5" subjects_affected="104" subjects_at_risk="671"/>
              </event>
              <event>
                <sub_title>CHILLS</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="164"/>
                <counts group_id="E5" subjects_affected="28" subjects_at_risk="671"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="164"/>
                <counts group_id="E5" subjects_affected="83" subjects_at_risk="671"/>
              </event>
              <event>
                <sub_title>RHINITIS</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="164"/>
                <counts group_id="E5" subjects_affected="97" subjects_at_risk="671"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="53" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="41" subjects_at_risk="164"/>
                <counts group_id="E5" subjects_affected="186" subjects_at_risk="671"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="164"/>
                <counts group_id="E5" subjects_affected="41" subjects_at_risk="671"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="164"/>
                <counts group_id="E5" subjects_affected="64" subjects_at_risk="671"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="164"/>
                <counts group_id="E5" subjects_affected="30" subjects_at_risk="671"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>SOMNOLENCE</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="164"/>
                <counts group_id="E5" subjects_affected="103" subjects_at_risk="671"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>EATING DISORDER</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="164"/>
                <counts group_id="E5" subjects_affected="121" subjects_at_risk="671"/>
              </event>
              <event>
                <sub_title>IRRITABILITY</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="164"/>
                <counts group_id="E5" subjects_affected="134" subjects_at_risk="671"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trial Disclosure Manager</name_or_title>
      <organization>Seqirus</organization>
      <email>Seqirus.ClinicalTrials@Seqirus.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

